

Special Issue

Metabolomics in Drug Metabolism, Drug-Drug Interactions, and Drug Toxicity

Message from the Guest Editor

Issues related to drug safety remain a major bottleneck in drug discovery and development. Recent technological advancements in metabolomics have helped us to gain insights into the mechanisms of drug toxicity, translatability to humans, prediction of safety events, mitigation of side effects, and development of safety biomarkers. Metabolomics applied to drug metabolism, drug–endobiotic interactions, and drug–drug interactions offers an ideal opportunity to study the toxicological effects of drugs. This Special Issue is devoted to metabolomics in drug metabolism, drug–drug interactions, and drug toxicity. The topics that will be covered include studies on the metabolomic analyses of the fate of drugs and host responses to drugs (including new modalities such as peptides, antibody–drug conjugates, protein therapeutics, and oligonucleotide therapeutics), as well as endogenous probes for drug–drug interactions. Additional topics include metabolomic analyses of studying the mechanism, prediction, and safety biomarkers of drug toxicity.

Guest Editor

Dr. Pengcheng Wang

Translational Medicine, Novartis Biomedical Research, Cambridge, MA 02139, USA

Deadline for manuscript submissions

closed (30 June 2025)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.1
Indexed in PubMed



mdpi.com/si/192517

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.1
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-
Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 12.6 days after submission; acceptance to publication is undertaken in 3.7 days (median values for papers published in this journal in the first half of 2026).